Vanguard Group Inc. Sells 37,508 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Vanguard Group Inc. decreased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 0.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,692,763 shares of the company's stock after selling 37,508 shares during the period. Vanguard Group Inc. owned about 11.47% of Prestige Consumer Healthcare worth $325,569,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Deutsche Bank AG grew its stake in shares of Prestige Consumer Healthcare by 21.1% in the third quarter. Deutsche Bank AG now owns 27,940 shares of the company's stock worth $1,598,000 after acquiring an additional 4,867 shares in the last quarter. Connors Investor Services Inc. acquired a new position in shares of Prestige Consumer Healthcare during the third quarter worth $1,569,000. Walleye Capital LLC acquired a new position in shares of Prestige Consumer Healthcare during the third quarter worth $249,000. Comerica Bank grew its stake in shares of Prestige Consumer Healthcare by 2.1% during the third quarter. Comerica Bank now owns 67,077 shares of the company's stock worth $3,836,000 after purchasing an additional 1,370 shares in the last quarter. Finally, Morgan Stanley grew its stake in shares of Prestige Consumer Healthcare by 8.4% during the third quarter. Morgan Stanley now owns 667,499 shares of the company's stock worth $38,174,000 after purchasing an additional 51,831 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Insider Activity

In related news, SVP Mary Beth Fritz sold 5,336 shares of Prestige Consumer Healthcare stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $69.00, for a total transaction of $368,184.00. Following the sale, the senior vice president now owns 15,934 shares of the company's stock, valued at approximately $1,099,446. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Price Performance

PBH traded down $0.07 on Thursday, hitting $72.56. 233,190 shares of the company were exchanged, compared to its average volume of 248,154. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.92 and a current ratio of 3.09. The business's fifty day moving average is $68.65 and its 200 day moving average is $62.53. Prestige Consumer Healthcare Inc. has a fifty-two week low of $55.96 and a fifty-two week high of $75.31. The firm has a market capitalization of $3.60 billion, a P/E ratio of -44.24, a price-to-earnings-growth ratio of 2.08 and a beta of 0.52.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, February 8th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.04 by $0.02. The firm had revenue of $282.74 million for the quarter, compared to analyst estimates of $280.25 million. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive return on equity of 14.09%. Prestige Consumer Healthcare's revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the business earned $1.04 earnings per share. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.33 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on PBH shares. TheStreet upgraded shares of Prestige Consumer Healthcare from a "c+" rating to a "b-" rating in a research note on Monday, February 12th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, February 10th. One equities research analyst has rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of "Moderate Buy" and an average target price of $110.00.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.